A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006)

AIDS

Volumn 13, Issue 4, 1999, Pages 479-486

  Musoke, Philippa ^a   Guay, Laura A ^b   Bagenda, Danstan ^a   Mirochnick, Mark ^c   Nakabiito, Clemensia ^a   Fleming, Thomas ^d   Elliott, Terry ^d   Horton, Scott ^d   Dransfield, Kevin ^e   Pav, Joseph W ^e   Murarka, Amal ^b   Allen, Melissa ^f   Fowler, Mary Glenn ^g   Mofenson, Lynne ⁱ   Hom, David ^h   Mmiro, Francis ^a   Jackson, J Brooks ^b  

^a MAKERERE UNIVERSITY   (Uganda)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^f FAMILY HEALTH INTERNATIONAL   (United States)

^g NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^h CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ Carnegie Building ^*

Author keywords

HIV vertical transmission; Nevirapine; Pharmacokinetics; Uganda

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ARTICLE; BLOOD; CLINICAL TRIAL; DRUG TOLERANCE; FEMALE; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NEWBORN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PREGNANCY; PREGNANCY COMPLICATION; SAFETY; UGANDA; VIROLOGY;

ANTI-HIV AGENTS; CONSUMER PRODUCT SAFETY; DRUG TOLERANCE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT, NEWBORN; NEVIRAPINE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; UGANDA;

EID: 0033545463     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199903110-00006     Document Type: Article

References (17)

1. Rouzioux C, Costagliola H, Burgard M, et al.: Estimated timing of mother-to-child human immunodeficiency virus type 1 transmission by use of a Markov model: The HIV Infection in Newborns French Collaborative Study Group. Am J Epidemiol 1995, 142:1330-1337.
2. Bertolli J, St Louis ME, Simonds RJ, et al.: Estimating the timing of mother-to-child transmission of human immunodeficiency virus in a breast feeding population in Kinshasha, Zaire. J Infect Dis 1996, 174:722-726.
3. Connor F, Sperling R, Gelber R, et al.: Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment, N Engl J Med 1994, 331:1173-1180.
4. Sperling RS, Shapiro DE, Coombs RW, et al.: Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. N Engl J Med 1998, 335:1621-1629.
5. Merluzzi V, Hargrave K, Granger K, et al.: Inhibition of HIV-1 replication by a non-nucleoside reverse transcriptase inhibitor. Science 1990, 250:1411-1413.
6. Cheeseman S, Havlir D, McLaughlin M, et al.: Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus. J AIDS 1995, 8:141-151.
7. Havlir D, Cheeseman S, McLaughlin M, et al.: High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis 1995, 171:537-545.
8. Cheeseman S, Hattox S, McLaughlin M, et al.: Pharmacokinetics of nevirapine: initial single-rising-dose study in humans. Antimicrob Agents Chemother 1993, 37:178-182.
9. Brennan CA, Lund JK, Golden A, et al.: Serologic and phylogenetic characterization of HIV-1 subtypes in Uganda. AIDS 1997; 11:1823-1832.
10. Mirochnick M, Fenton T, Gagnier P, et al.: Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. J Infect Dis 1998, 178:368-374.
11. Hollinger FB, Bremer JW, Myers LF, et al.: Standardization of sensitive human immunodeficiency virus coculture procedures and establishment of a multicenter quality assurance program for the AIDS Clinical Trials Group. J Clin Microbiol 1992, 30:1787-1794.
12. Lamson MJ, Cort S, Sabu JP, MacGregor TR, Keirns JJ. Effects of gender on the single and multiple dose pharmacokinetics of nevirapine 200 mg/day. International Conference on AIDS. Vancouver, Canada. 7-12 July 1996 [abstract XI] .
13. Murphy RL, Montaner JL, Nevirapine: a review of its development, pharmacological profile and potential for clinical use. Expert Opin Invest Drugs 1996, 5:1183-1199.
14. Luzuriaga K, Bryson Y, McSherry G, et al.: Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children. J Infect Dis 1996, 174:713-721.
15. Leeder JS, Kearns GL. Pharmacogenetics in pediatrics: implications for practice. Pediatr Clin N Am 1997, 44:55-77.
16. Zhang H, Dornadula G, Wu Y, Havlir D, Richman DD, Pomerantz RJ. Kinetic analysis of intravirion reverse transcription in the blood plasma of human immunodeficiency virus type I-infected individuals: direct assessment of resistance to reverse transcriptase inhibitors in vivo. J Virology 1996, 70:628-634.
17. Mmiro F, Ndugwa C, Kenya-Mugisha, et al.: Effect of human immunodeficiency virus-1 infection on outcome of pregnancy in Ugandan women. Pediatr AIDS HIV Infect 1993, 4:67-73.